| Literature DB >> 31692132 |
Wassilios G Meissner1,2,3,4, Pierre-Olivier Fernagut2,3,5,6, Benjamin Dehay2,3, Patrice Péran7, Anne Pavy-Le Traon8, Alexandra Foubert-Samier1,2,9, Miguel Lopez Cuina2,3, Erwan Bezard2,3, François Tison1,2,3, Olivier Rascol10.
Abstract
Multiple system atrophy (MSA) is a rare and fatal neurodegenerative disorder characterized by a variable combination of parkinsonism, cerebellar impairment, and autonomic dysfunction. The pathologic hallmark is the accumulation of aggregated α-synuclein in oligodendrocytes, forming glial cytoplasmic inclusions, which qualifies MSA as a synucleinopathy together with Parkinson's disease and dementia with Lewy bodies. The underlying pathogenesis is still not well understood. Some symptomatic treatments are available, whereas neuroprotection remains an urgent unmet treatment need. In this review, we critically appraise significant developments of the past decade with emphasis on pathogenesis, diagnosis, prognosis, and treatment development. We further discuss unsolved questions and highlight some perspectives.Entities:
Keywords: MSA; diagnosis; prognosis; treatment; α-synuclein
Mesh:
Year: 2019 PMID: 31692132 DOI: 10.1002/mds.27894
Source DB: PubMed Journal: Mov Disord ISSN: 0885-3185 Impact factor: 10.338